協創數據(300857.SZ):積極打造涵蓋機器狗、人形機器人等先進智能製造能力的綜合平台
格隆匯5月13日丨協創數據(300857.SZ)在投資者互動平台表示,公司積極佈局機器人領域,公司建設的無人工廠通過機器人替代人工,推動製造成本大幅下降,公司發佈的FCloud 智能體訓推創新平台產品,具備為具身機器人、生物製藥、芯片製造、金融等領域提供訓推服務的能力。公司已設立協創具身智能機器人(深圳)有限公司,未來公司亦將依託自身在人工智能、大數據、機器學習和自動化控制技術上的優勢,積極打造涵蓋機器狗、人形機器人等先進智能製造能力的綜合平台。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.